SCHEMBL20366368

SCHEMBL20366368

Cn1cc(Br)cc(NC(=O)O)c1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 7/20 0.39
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NPY4R P50391 3/20 0.35
GPR35 Q9HC97 2/20 0.35
BRD4 O60885 1/20 0.34
RXFP1 Q9HBX9 2/20 0.33
MAPT P10636 1/20 0.33
HIF1A Q16665 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
NPY5R Q15761 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21227687 0.86 ALDH1A1 (0.41) MAP2K1POLBGAATDP1RAB9A
SCHEMBL12602979 0.83 SMN1; SMN2 (0.42) MAP2K1POLBGAATDP1BRD4
SCHEMBL21227681 0.82 GAA (0.43) POLBGAAMEN1KMT2ANPY4R
SCHEMBL24374804 0.82 HIF1A (0.50) POLBTDP1MEN1RAB9AKMT2A
SCHEMBL16342388 0.80 BRD4 (0.46) GAAMEN1KMT2ABRD4NPSR1
SCHEMBL12602996 0.80 BTK (0.46) POLBGAATDP1MEN1KMT2A
SCHEMBL16651233 0.79 CNR2 (0.41) RAB9ABRD4RXFP1
SCHEMBL16651308 0.78 BRD4 (0.36) MAP2K1BRD4
SCHEMBL16342375 0.77 AAK1 (0.43) GAAKMT2AGPR35BRD4RXFP1
SCHEMBL22631630 0.76 MALT1 (0.49) MEN1KMT2ANPY4RGPR35RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023592-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023592-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 MAP2K1 1407/4885POLB 586/4885GAA 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.